Glyx Therapeutics is at the forefront of the development of lipid-linked anionic oligosaccharides (LAOs) for the treatment of tauopathies, including Alzheimer’s disease. This innovative approach offers a promising alternative to existing amyloid-based therapies (monoclonal antibodies).
Would you like to edit the information on your profile page?
Oops! We could not locate your form.